UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM | |||||||||||||||||||
(Mark One) EXCHANGE ACT OF 1934 OR ACT OF 1934 For the fiscal year ended OR EXCHANGE ACT OF 1934 For the transition period from __________ to __________ OR EXCHANGE ACT OF 1934 Date of event requiring this shell company report __________ Commission file number | |||||||||||||||||||
(Exact name of registrant as specified in its charter and translation of Registrant’s name into English) The | |||||||||||||||||||
(Jurisdiction of incorporation or organization) | |||||||||||||||||||
(Address of principal executive offices) argenx BV | |||||||||||||||||||
(Name, telephone, e-mail and/or facsimile number and address of company contact person) Securities registered or to be registered pursuant to Section 12(b) of the Act: | |||||||||||||||||||
Title of each class: | Trading | Name of each exchange on which registered: | |||||||||||||||||
Symbol: | |||||||||||||||||||
* Not for trading, but only in connection with the registration of the American Depositary Shares. Securities registered or to be registered pursuant to Section 12(g) of the Act: None. Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None. Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report: As of December 31, 2025 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes ☐ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. | |||||||||||||||||||
Accelerated filer ☐ | Non-accelerated filer ☐ | Emerging growth company | |||||||||||||||||
If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act. ☐ † The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012. Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐ Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing: | |||||||||||||||||||
U.S. GAAP ☐ | by the International Accounting Standards Board ☒ | Other ☐ | |||||||||||||||||
If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow. Item 17 ☐ Item 18 ☐ If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No (APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS.) Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☐ No ☐ | |||||||||||||||||||
ii |
Page |
iii |
iv |
v |
vi |
vii |
viii |
1 | ||
2 | ||
4 | ||
5 | ||
6 | ||
8 | ||
9 | ||
10 | ||
11 | ||
12 | ||
13 | ||
14 | ||
15 | ||
16 | ||
19 | ||
20 | ||
21 | ||
22 | ||
23 | ||
24 | ||
25 | ||
26 | ||
27 | ||
28 | ||
30 | ||

31 | ||
Program | Indication | Preclinical | Phase 1 | Proof of Concept | Registrational | Commercial | ||||||
VYVGART | gMG | |||||||||||
ITP (Japan) | ||||||||||||
VYVGART HYTRULO | gMG | |||||||||||
CIDP | ||||||||||||
efgartigimod | Seronegative gMG | |||||||||||
Ocular MG | ||||||||||||
Primary ITP | ||||||||||||
Graves’ Disease | ||||||||||||
Myositis | ||||||||||||
SjD | ||||||||||||
Systemic Sclerosis | ||||||||||||
AMR | ||||||||||||
empasiprubart | MMN | |||||||||||
DGF | ||||||||||||
CIDP | ||||||||||||
adimanebart | CMS | |||||||||||
SMA | ||||||||||||
ARGX-213 | Undisclosed | |||||||||||
ARGX-121 | IgA Nephropathy | |||||||||||
ARGX-124 | Undisclosed | |||||||||||
ARGX-109 | Undisclosed | |||||||||||
TSP-101 | Undisclosed | |||||||||||
ARGX-118 | Undisclosed | |||||||||||
ARGX-125 | Undisclosed |
NEUROLOGY | NEPHROLOGY AND HEMATOLOGY | ENDOCRINOLOGY | RHEUMATOLOGY | UNDISCLOSED |
Product | Indication | Geography | Regulatory Status | |||||
VYVGART IV | VYVGART | gMG | US | Approved | ||||
VYVGART | gMG | Europe | Approved | |||||
VYVGART | gMG | Canada | Approved | |||||
VYVGART | gMG | Israel | Approved | |||||
VYVGART | gMG | Japan | Approved | |||||
VYVGART | gMG | The UK | Approved | |||||
VYVGART | gMG | China | Approved | |||||
VYVGART | gMG | Australia | Approved | |||||
VYVGART | gMG | Kuwait | Approved | |||||
VYVGART | gMG | Saudi Arabia | Approved | |||||
VYVGART | gMG | Korea (the Republic of) | Approved | |||||
VYVGART | gMG | United Arab Emirates | Approved | |||||
VYVGART | gMG | Switzerland | Approved | |||||
Pending | gMG | Brazil | Submitted | |||||
VYVGART | gMG | Singapore | Approved | |||||
VYVGART | ITP | Japan | Approved | |||||
VYVGART SC | VYVGART HYTRULO | gMG | US | Approved | ||||
VYVGART HYTRULO | CIDP | US | Approved | |||||
VYVGART | gMG | Australia | Approved | |||||
VYVGART | CIDP | Australia | Submitted | |||||
VYVGART | gMG | Europe | Approved | |||||
VYVGART | CIDP | Europe | Approved | |||||
VYVGART | gMG | Switzerland | Approved | |||||
VYVGART | CIDP | Switzerland | Submitted | |||||
VYVGART | gMG | The UK | Approved | |||||
VYVGART | CIDP | The UK | Approved | |||||
VYVGART SC | gMG | Israel | Approved | |||||
VYVGART HYTRULO | gMG | China | Approved | |||||
VYVGART HYTRULO | CIDP | China | Approved | |||||
VYVDURA | gMG | Japan | Approved | |||||
VYVDURA | CIDP | Japan | Approved | |||||
PFS | VYVDURA | gMG | Japan | Approved | ||||
VYVDURA | CIDP | Japan | Approved | |||||
VYVGART HYTRULO | gMG | U.S. | Approved | |||||
VYVGART HYTRULO | CIDP | U.S. | Approved | |||||
VYVGART | gMG | Europe | Approved | |||||
VYVGART | CIDP | Europe | Approved | |||||
VYVGART SC | gMG | Canada | Approved | |||||
VYVGART SC | CIDP | Canada | Approved | |||||
VYVGART | gMG | The UK | Approved | |||||
VYVGART | CIDP | The UK | Approved | |||||
VYVGART | gMG | Australia | Approved | |||||
VYVGART | CIDP | Australia | Submitted | |||||
VYVGART | Switzerland | Submitted | ||||||
VYVGART | gMG | Israel | Submitted | |||||
VYVGART | CIDP | Israel | Submitted |
35 | ||

Clinical Trial | Stage | Indication | Patients | Primary Endpoint | Status | |||||
ADAPT | Registrational | gMG | The proportion of responders based on the Myasthenia Gravis Activities of Daily Living (MG-ADL) score | Marketed | ||||||
ADAPT-SC | Registrational | gMG | The proportion of responders based on the Myasthenia Gravis Activities of Daily Living (MG-ADL) score | Marketed | ||||||
ADAPT- SERON | Registrational | Seronegative gMG | 119 | MG-ADL total score change from baseline to day 29 (w4) | Positive clinical trial results reported in 2025 with expected PDUFA date of May 10, 2026 | |||||
ADAPT- OCULUS | Registrational | Ocular MG | 141 | Change in MGII PRO ocular score from baseline to day 29 (w4) | Positive clinical trial results reported in February 2026 | |||||
ADHERE | Registrational | CIDP | 322 | The hazard ratio for the time to first adjusted INCAT deterioration | Marketed | |||||
ADVANCE- IV | Registrational | ITP | The proportion of patients that achieved sustained platelet response | Marketed |
36 | ||
Clinical Trial | Stage | Indication | Patients | Primary Endpoint | Status | |||||
ADVANCE- NXT | Registrational | ITP | 63 | Extent of disease control (cumulative number of weeks over the planned 24-week treatment period with platelet counts of ≥ 50×109/L | Ongoing clinical trial results expected in 4Q 2026 | |||||
ALKIVIA | Registrational | Myositis | Target 240 | The total improvement score (TIS) at the end of treatment period | Ongoing clinical trial results expected in 3Q 2026 | |||||
UNITY | Registrational | SjD | Target 580 | The change from baseline on the ClinESSDAI score (w48) | Ongoing clinical trial results expected in 2H 2027 | |||||
In partnership with Zai Lab | PoC | LN | Target 60 | The change in urine protein creatinine ratio from baseline to end of the treatment period | Clinical trial discontinued in 2025 | |||||
uplighTED | Registrational | TED | Target 108/ trial | Percentage of participants who were proptosis responders at week 24 | Clinical trial discontinued in 2025 | |||||
shAMRock | PoC | AMR | Target 30 | Safety and tolerability. Efficacy measures such as estimated glomerular filtration rate, histology and urine protein creatinine ratio are captured in the secondary endpoints | Ongoing clinical trial | |||||
ADAPT- JUNIOR IV | Phase 2/3 | gMG | Target over 12 | To confirm an age-adjusted optimum dose of efgartigimod IV and provide (model- predicted) evidence for a treatment response | Ongoing clinical trial | |||||
ADAPT- JUNIOR SC | Phase 2/3 | gMG | Target over 12 | To confirm an appropriate dose of efgartigimod PH20 SC in pediatric participants with gMG | Ongoing clinical trial | |||||
Other clinical trials | PoC | AIE | To be confirmed | Ongoing clinical trial | ||||||
PoC | AIM | To be confirmed | To be confirmed | Ongoing clinical trial |
38 | ||
39 | ||

40 | ||
41 | ||
42 | ||
46 | ||
47 | ||
48 | ||
49 | ||
50 | ||
51 | ||
52 | ||
53 | ||
56 | ||
57 | ||
58 | ||
59 | ||
60 | ||
61 | ||
62 | ||
Number of shares outstanding on December 31, 2023 | 59,194,488 | |
Exercise of stock options | 1,478,225 | |
Vesting of RSUs | 88,244 | |
Number of shares outstanding on December 31, 2024 | 60,760,957 | |
Exercise of stock options | 986,507 | |
Vesting of RSUs | 135,842 | |
Number of shares outstanding on December 31, 2025 | 61,883,306 | |
Exercise of stock options | 179,582 | |
Number of shares outstanding on February 19, 2026 | 62,062,888 |
As per December 31, 2025 | ||||
Name | Country | Participation | ||
argenx SE | the Netherlands | 100% | ||
argenx B.V. | Belgium | 100% | ||
argenx Benelux B.V. | Belgium | 100% | ||
argenx US, Inc. | USA | 100% | ||
argenx Australia Pty. Ltd. | Australia | 100% | ||
argenx Austria Services GmbH | Austria | 100% | ||
argenx Brasil Produtos Farmacêuticos Ltda | Brazil | 100% | ||
argenx Canada Inc. | Canada | 100% | ||
argenx France SAS | France | 100% | ||
argenx Germany GmbH | Germany | 100% | ||
argenx Italy S.r.l. | Italy | 100% | ||
argenx Japan KK. | Japan | 100% | ||
argenx Netherlands Services B.V. | the Netherlands | 100% | ||
argenx Spain S.L. | Spain | 100% | ||
argenx Spain S.L. - Sucursal em Portugal | Portugal | 100% | ||
argenx Switzerland, S.A. | Switzerland | 100% | ||
argenx UK Ltd. | United Kingdom | 100% | ||
Broteio Pharma B.V. | the Netherlands | 100% | ||

65 | ||
Facility location | Use | Approx. size (m2) | Lease expiry | |||
Zwijnaarde, Belgium (leased) | Operations and Laboratory Space | 5,339 | September 30, 2031 | |||
Zwijnaarde, Belgium (leased) | Office Space | 3,765 | September 30, 2036 | |||
Boston, Massachusetts (leased) | Office Space | 2,379 | August 31, 2030 | |||
Tokyo, Japan (leased) | Office Space | 546 | January 17, 2027 |
66 | ||
67 | ||
68 | ||
Year Ended December 31, | ||||||||
(in thousands of $ except for shares and EPS) | 2025 | 2024 | % Change | |||||
Product net sales | $ | 4,151,316 | $ | 2,185,883 | 90% | |||
Other operating income1) | 96,734 | 66,156 | 46% | |||||
Total operating income | 4,248,050 | 2,252,039 | 89% | |||||
Cost of sales | (450,665) | (227,289) | 98% | |||||
Research and development expenses | (1,364,132) | (983,423) | 39% | |||||
Selling, general and administrative expenses | (1,367,057) | (1,055,337) | 30% | |||||
Loss from investment in a joint venture | (12,390) | (7,644) | 62% | |||||
Total operating expenses | (3,194,244) | (2,273,693) | 40% | |||||
Operating profit/(loss) | $ | 1,053,806 | $ | (21,654) | ||||
Financial income | 163,091 | 157,509 | 4% | |||||
Financial expense | (4,082) | (2,464) | 66% | |||||
Exchange gains/(losses) | 65,792 | (48,211) | (236)% | |||||
Profit for the year before taxes | $ | 1,278,607 | $ | 85,180 | ||||
Income tax benefit | $ | 13,428 | $ | 747,860 | (98)% | |||
Profit for the year | $ | 1,292,035 | $ | 833,040 | 55% | |||
Weighted average number of shares used for basic profit per share | 61,295,149 | 59,855,585 | ||||||
Basic profit per share (in $) | 21.08 | 13.92 | 51% | |||||
Weighted average number of shares used for diluted profit per share | 66,029,215 | 65,177,815 | ||||||
Diluted profit/(loss) per share (in $) | 19.57 | 12.78 | 53% | |||||
69 | ||
70 | ||
72 | ||
73 | ||
74 | ||
Name | Age | Position | Nationality | Date of Initial Appointment | Date of last (re-) Appointment | Term expiration | ||||||
Tim Van Hauwermeiren | 53 | CEO and executive director | Belgium | July 15, 2008 | May 10, 2022 | AGM 20261) | ||||||
Peter Verhaeghe | 67 | Non-Executive Director (chairperson) | Belgium | October 15, 2008 | May 7, 2024 | AGM 20262) | ||||||
Ana Céspedes | 52 | Non-Executive director | Spain | December 12, 2022 | December 12, 2022 | AGM 2026 | ||||||
James Daly | 64 | Non-Executive Director | U.S. | May 8, 2018 | May 10, 2022 | AGM 2026 | ||||||
Donald deBethizy3) | 75 | Non-Executive Director1) | U.S. | May 13, 2015 | May 2, 2023 | AGM 2025 | ||||||
Pamela Klein | 64 | Non-Executive Director | U.S. | April 28, 2016 | May 7, 2024 | AGM 2026 | ||||||
Brian Kotzin | 77 | Non-Executive Director | U.S. | May 7, 2024 | May 7, 2024 | AGM 2028 | ||||||
Steve Krognes | 57 | Non-Executive Director | U.S. and Norway | February 27, 2023 | February 27, 2023 | AGM 2027 | ||||||
Anthony Rosenberg | 72 | Non-Executive Director1) | UK | April 26, 2017 | May 27, 2025 | AGM 2027 | ||||||
Camilla Sylvest | 53 | Non-Executive director | Denmark | September 8, 2022 | September 8, 2022 | AGM 2026 |
75 | ||
76 | ||
77 | ||
Name | Number of meetings attended in 2025 since appointment (and up to resignation, as applicable) | Attendance % | ||
Peter Verhaeghe | 6 | 100% | ||
Tim Van Hauwermeiren | 6 | 100% | ||
Steve Krognes | 6 | 100% | ||
Donald deBethizy1) | 3 | 100% | ||
Pamela Klein | 6 | 100% | ||
Anthony Rosenberg (vice-chairperson) | 6 | 100% | ||
James Daly | 6 | 100% | ||
Camilla Sylvest | 6 | 100% | ||
Ana Céspedes | 6 | 100% | ||
Brian Kotzin | 6 | 100% |
Name | Number of meetings attended in 2025 since appointment (and up to resignation, as applicable) | Attendance % | ||
Peter Verhaeghe | 5 | 100% | ||
Donald deBethizy1) | 3 | 100% | ||
Pamela Klein | 5 | 100% | ||
Anthony Rosenberg | 5 | 100% | ||
James Daly | 5 | 100% | ||
Camilla Sylvest | 5 | 100% | ||
Ana Céspedes | 5 | 100% | ||
Brian Kotzin | 5 | 100% |
78 | ||
Name | Age | Position | Nationality | Date of Initial Appointment | ||||
Tim Van Hauwermeiren1) | 53 | CEO and Executive Director | Belgium | July 15, 2008 | ||||
Karen Massey2) | 47 | COO | Australia | March 13, 2023 | ||||
Karl Gubitz | 56 | CFO | South Africa and U.S. | June 1, 2021 | ||||
Peter Ulrichts | 46 | Chief Scientific Officer | Belgium | January 1, 2023 | ||||
Malini Moorthy | 56 | General Counsel and Corporate Secretary | Canada and U.S. | February 14, 2022 | ||||
Luc Truyen | 61 | Chief Medical Officer | Belgium and U.S. | April 1, 2022 | ||||
Arjen Lemmen | 41 | Vice-President Corporate Development & Strategy | The Netherlands | May 1, 2016 | ||||
Andria Wilk | 53 | Global Head of Quality | UK | January 13, 2020 |
79 | ||
81 | ||
82 | ||
83 | ||
Pay Element | 2021 Remuneration Policy (77% approval) | 2025 Remuneration Policy (approx. 96% approval) | ||
Base Pay | •Set at or around the 50th percentile of U.S. peer group for U.S.-based executives, and around the 75th percentile of EU peer group for EU-based executives. | •Targets the 50th percentile of the Executives in the peer group. | ||
Benefits and Pension | •Customary fringe benefits including pension contributions, hospitalization and disability insurance, severance arrangement, company car, phone, and laptop. | •Benefits and pension contributions aligned with those of other employees within the same legal entity and in accordance with local market practice. | ||
Short-Term Incentive | •Cash-based target STI for CEO is 60% of base pay at 100% target achievement; maximum payout of 120% of base pay. •Typically 60% of targets related to quantitative targets (building the business) and 40% of targets related to qualitative targets (building the organization). Target mix was not fixed. | •Quantum unchanged from 2021 Remuneration Policy. •Majority of targets are quantitative and at least 50% of STI linked to financial performance targets. Qualitative targets will be milestone-based to the extent possible. | ||
Long-Term Incentive | •100% time-based LTI (no performance conditions). Plan consisting of time-based stock options and time-based RSUs. •No cap on LTI opportunities included. •Stock options vest 1/3 after 1 year and then in monthly installments until the end of the 3-year period. RSUs vest 25% on each anniversary of the grant date. | •100% risk-based; LTI with no less than 50% PSUs and no more than 50% stock options. •The annual LTIP opportunity is 7x base pay at target / 10x at maximum. •As of 2026, stock options and PSUs have a 3-year cliff vesting period; no equity vests before the end of the 3 years. | ||
Shareholding Requirements | •No shareholding requirements. | •Equal to 6x annual base pay in the form of company equity (excluding non-vested RSUs/ PSUs and stock options), to be built up over a maximum of five years. | ||
Clawback provisions | •No clawback policy | •Clawback policy in place applicable to variable remuneration paid out on the basis of financial information which is subsequently restated. | ||
Recruitment Provisions | •Board may grant additional 1x regular equity grant as sign-on award. | •May offer buyout awards to compensate for value lost by changing employers. |
84 | ||
Pay Element | 2021 Remuneration Policy (77% approval) | 2025 Remuneration Policy (approx. 96% approval) | ||
Leaver Provisions | •No explicit leaver provisions. | •STIP: Legacy provision for current Executive Director to be pro-rated for time and performance upon termination. For any other Executive Director, there will be no STI payout unless in service on 31 December of that performance year. •LTIP: Legacy provision for current Executive Director provides for immediate and full vesting at time of termination, except for the PSUs. For any other Executive Director, upon leaving the Company, unvested stock options and PSUs are forfeited without compensation. During performance period other than dismissal for cause or underperformance, vesting of PSUs will be pro- rated for time and performance at the end of 3- year performance period. | ||
Peer Group | •Reference group includes European and U.S.- based integrated, commercial-stage life science companies. Selected for comparability in size, activities and market presence | •Reference group comprises European and U.S.- based commercial-stage biopharmaceutical companies selected for comparability in innovation focus, global reach, size (revenue and market value relative to argenx), market presence and public listing. |
Pay Element | 2021 Policy (77% approval) | 2025 Policy (96% approval) | ||
Cash | •Benchmarked regularly fees could be adjusted as necessary based on regular benchmarking exercises to ensure continued fair and competitive remuneration. | •Annual cash retainer fee targets the 50th percentile of the peer group and benchmarked annually. 2025 Board of Directors membership fee: $60k per year, with additional $59.5k for the chairperson. Committee members receive (depending on the committee) $10,000-12,500 for membership or $20,000-25,000 for chairmanship. | ||
Equity | •Share options and/or restricted share units in an amount that is at or around the 50th percentile of the U.S. companies in our reference group. Per 2021, we granted 2,700 stock options and 600 RSUs to each Non-Executive Director. Equity granted was adjusted on the basis of benchmark outcomes and in consideration of developments in the composition of equity incentives offered by argenx to key persons outside the Board of Directors, including company employees. •RSUs vest over 4 years and stock options vesting over 3 years. •Since 2024, stock options no longer granted to Non-Executive Directors to avoid any perceived effect on independence; switched to granting RSUs. | •Annual equity grant of $400,000 in the form of restricted shares with no vesting conditions, targeting the 50th percentile of the peer group and subject to annual review. No shares may be sold until after the 4th anniversary of the grant date, except to the extent necessary to cover immediate tax obligations resulting from the vest. •Restricted shares are not subject to vesting conditions. 4-year holding requirement for equity grants (except sales to cover immediate tax obligations). |
85 | ||
Pay Element | 2021 Policy (77% approval) | 2025 Policy (96% approval) | ||
Shareholding Requirements | •No shareholding requirements. | •Holding of 5x annual Board of Director membership retainer fees (as at the date of the 2025 Remuneration Policy, the annual retainer fee was $60,000), to be built over a period of 5 years. | ||
Special travel allowance | •No special travel allowance. | •Special travel allowance of $5,000 for in-person attendance at each board meeting held outside of a Non-Executive Director’s official continent of residence. |
86 | ||
87 | ||
Performance Metric and Weighting | Measurement (how the Board of Directors evaluated the target) | Threshold | Target | Max | Achievement | Vesting | Actual pay-out | |||||||
Revenue (50%) | •Annual operating budget revenue target delivered •Successful PFS self- administration approval and launch in the U.S. | 80% of annual operating budget target | 100% annual operating budget | 120% annual operating budget | 120% annual operating budget | 100% | 496,296 | |||||||
Pipeline (20%) | •MG combo clinical trial launched Q3 and/or •Nominate 2 new ARGX-xxx candidates and graduate 3 discovery projects to lead identification (PPD) | •Combo trial launched •1 new ARGX- xxx candidate nominated •2 molecules graduated | •Combo trial launched •2 new ARGX-xxx candidate nominated •3 molecules graduated | •Combo trial launched in Q3 •3 new ARGX- xxx candidate nominated •4 molecules graduated | •Combo trial launched •2 new ARGX-xxx candidate nominated •3 molecules graduated | 20% | 99,259 | |||||||
Innovation (20%) | •Champion key innovation projects AND •All variable pay eligible employees have 1x performance goal linked to innovation AND •Key innovations recognized, celebrated and cascaded throughout the Company | •1x innovation projects championed AND •80% of employees 1x performance goal linked to innovation AND •3x key innovation celebrated at the Corporate update | •3x innovation projects championed AND •90% of employees 1x performance goal linked to innovation AND •3x key innovation celebrated at the Corporate update | •5x innovation projects championed AND •100% of employees 1x performance goal linked to innovation AND •3x key innovation celebrated at the Corporate update | •3x innovation projects championed AND •90% of employees 1x performance goal linked to innovation AND •3x key innovation celebrated at the Corporate update | 20% | 99,259 | |||||||
Scaling the argenx way (10%) | •Succession plan in place for key senior leaders | No plan in place | Plan in place | N/A | Plan in place | 10% | 49,630 |
88 | ||
Performance Metric and Weighting | Measurement (how the Board of Directors evaluated the target) | Threshold | Target | Max | Achievement | Vesting | Actual pay-out | |||||||
Revenue (30%) | •Annual operating budget revenue target delivered AND •Successful PFS self- administration approval and launch in the U.S. | 80% of annual operating budget | 100% annual operating budget | 120% annual operating budget | 120% annual operating budget | 60% | 138,720 | |||||||
P&L (25%) | •Target effective tax rate in 2025 in line with annual operating budget | Effective tax rate 5% higher than annual operating budget | Effective tax rate in line with annual operating budget | Effective tax rate 5% lower than annual operating budget | Effective tax rate in line with annual operating budget | 25% | 57,800 | |||||||
Digital transformation (25%) | •Time required to close the quarter reduced by 50% AND •Annual operating budget process transformation AND •Financial accounts automation | 2/3 metrics achieved | 3/3 metrics achieved | Significant additional digitalization achieved beyond the 3/3 metric achieved | Significant additional digitalization achieved beyond the 3/3 metric achieved | 45% | 104,040 | |||||||
Scaling the argenx way (20%) | •Management headcount growth | Headcount growth >105% of annual operating budget | Headcount growth < 102% of annual operating budget | N/A | Headcount growth >105% of annual operating budget | 20% | 46,240 |
89 | ||
Performance Metric and Weighting | Measurement (how the Board of Directors evaluated the target) | Threshold | Target | Max | Achievement | Vesting | Actual pay-out | |||||||
Revenue (40%) | •Annual operating budget revenue target delivered •Successful PFS self- administration approval and launch in the U.S. | 80% of annual operating budget | 100% annual operating budget | 120% annual operating budget | 120% annual operating budget target | 80% | 296,656 | |||||||
Pipeline Acceleration (20%) | •PFS FDA approval | FDA acceptance | •FDA acceptance with no concerns and review on track | •FDA acceptance with PDUFA date < 6 months | •FDA acceptance with PDUFA date < 6 months | 40% | 148,328 | |||||||
Digital transformation (20%) | •Successful onboarding of Business Information Systems (BIS) leader and deliver on the BIS OGSM | 50% of the BIS OGSM measures delivered | Onboarded and delivered per annual operating budget AND 80% of the BIS OGSM measures delivered | Onboarded and delivered per annual operating budget AND 90% of the BIS OGSM measures delivered | •Onboarded and delivered per annual operating budget AND •90% of the BIS OGSM measures delivered | 35% | 129,787 | |||||||
Scaling the argenx way (20%) | •Successful onboarding of key hires and leadership teams' their OGSMs AND •Elevate the operational excellence community to a leadership community and their OGSM delivered | N/A | Accomplished | N/A | Accomplished | 20% | 74,164 |
90 | ||
CEO: Performance Metric, Target Area and Weighting | Measurement (how the Board of Directors evaluate the target) | |
Deliver continued VYVGART growth (50%) | 2026 financial plan revenue target delivered | |
Pipeline Acceleration (25%) | •Deliver Ocular MG, Myositis and MMN top line data read- outs in 2026 (10%) •On track to deliver SjD & CIDP data read-outs in 2027 (5%) •Not disclosed (10%) | |
Successful CEO transition (25%) | •Retention of key talent (12.5%) •Shareholder feedback on transition (12.5%) |
CFO: Performance Metric, Target Area and Weighting | Measurement (how the Board of Directors evaluate the target) | |
Deliver continued VYVGART growth (50%) | 2026 financial plan revenue target delivered | |
Capital allocation for long-term sustainable growth (25%) | Not disclosed | |
Champion digitization, automation, simplification and AI (10%) | Simplify and digitize financial processes | |
Scaling the argenx way (15%) | Headcount growth (15%) |
COO: Performance Metric, Target Area and Weighting | Measurement (how the Board of Directors evaluate the target) | |
Deliver continued VYVGART growth (50%) | 2026 financial plan revenue target delivered | |
Pipeline Acceleration (25%) | •Deliver Ocular MG, Myositis and MMN top line data read- outs in 2026 (10%) •On track to deliver SjD & CIDP data read-outs in 2027 (5%) •Not disclosed (10%) | |
Scaling the argenx way (15%) | Headcount growth (15%) | |
Successful CEO transition (10%) | •Retention of key talent (5%) •Shareholder feedback on transition (5%) |
91 | ||
92 | ||
Performance Metric | Target | Measurement (how the Board of Directors will evaluate the metric and why it has been chosen) | Threshold | Target | Max | |||||
Maximize the VYVGART opportunity (50%) | 2028 annual revenue | Minimum product net sales of undisclosed amount | Targets and Executive Director achievement will be disclosed retroactively in the 2028 remuneration report, published in 2029 | |||||||
Pipeline progression (40%) | (s)BLA Approvals (in addition to potential Seronegative gMG and Ocular MG) (20%) | Undisclosed number of new approvals | ||||||||
Phase (ii) Progression and/or IND / CTA Assets Submissions (20%) | Undisclosed number of new pipeline assets into phase 2 and/or undisclosed number of new additional pipeline assets IND / clinical trial application submitted | |||||||||
Scaling the argenx way (10%) | Talent retention | Three-year average voluntary employee turnover equal to or below 6.5% (target) or equal to or below 8.5% (floor) | ||||||||
93 | ||
Name | Cash retainer fees earned or paid in cash (in $)1) | RSU awards (in $) | Total (in $) | |||
Peter Verhaeghe | 142,000 | 394,903 | 536,903 | |||
Steve Krognes | 95,941 | 394,903 | 490,844 | |||
Pamela Klein | 77,500 | 394,903 | 472,403 | |||
Donald deBethizy2) | 37,547 | — | 37,547 | |||
Anthony Rosenberg | 82,500 | 394,903 | 477,403 | |||
James Daly | 97,500 | 394,903 | 492,403 | |||
Camilla Sylvest | 70,000 | 394,903 | 464,903 | |||
Ana Céspedes | 80,941 | 394,903 | 475,844 | |||
Brian Kotzin | 90,000 | 394,903 | 484,903 |
94 | ||
95 | ||
In $ | ||||||||||||||||||||||
Relevant body | Position | Fees in $ | Peter Verhaeghe | Steve Krognes | Pamela Klein | Donald deBethizy | Anthony Rosenberg | James Daly | Camilla Sylvest | Ana Céspedes | Brian Kotzin | |||||||||||
Board of Directors | Chairperson | 119,500 | 119,500 | — | — | — | — | — | — | — | — | |||||||||||
Member | 60,000 | — | 60,000 | 60,000 | 24,355 | 60,000 | 60,000 | 60,000 | 60,000 | 60,000 | ||||||||||||
Travel Allowance | 5,000 | — | 5,000 | 5,000 | — | — | 5,000 | — | 5,000 | 5,000 | ||||||||||||
Audit and Compliance Committee | Chairperson | 25,000 | — | 25,000 | — | — | — | — | — | — | — | |||||||||||
Member | 12,500 | 12,500 | — | — | — | 12,500 | 12,500 | — | — | — | ||||||||||||
Remuneration and Nomination Committee | Chairperson | 20,000 | — | — | — | 8,118 | — | — | — | 11,882 | — | |||||||||||
Member | 10,000 | 10,000 | 5,941 | — | — | — | — | — | 4,059 | — | ||||||||||||
Commercial Committee | Chairperson | 20,000 | — | — | — | — | — | 20,000 | — | — | — | |||||||||||
Member | 10,000 | — | — | — | — | 10,000 | — | 10,000 | — | — | ||||||||||||
Research and Development Committee | Chairperson | 20,000 | — | — | — | — | — | — | — | — | 25,000 | |||||||||||
Member | 12,500 | — | — | 12,500 | 5,074 | — | — | — | — | — | ||||||||||||
Total | 142,000 | 95,941 | 77,500 | 37,547 | 82,500 | 97,500 | 70,000 | 80,941 | 90,000 | |||||||||||||
RSUs granted in 20251) | ||||||||||
Name | # RSUs | Key terms | Value at grant 2) | Total | ||||||
Peter Verhaeghe | 703 | (1) | $ | 394,903 | $ | 394,903 | ||||
Ana Céspedes | 703 | (1) | 394,903 | 394,903 | ||||||
James Daly | 703 | (1) | 394,903 | 394,903 | ||||||
Pamela Klein | 703 | (1) | 394,903 | 394,903 | ||||||
Brian Kotzin | 703 | (1) | 394,903 | 394,903 | ||||||
Steve Krognes | 703 | (1) | 394,903 | 394,903 | ||||||
Anthony Rosenberg | 703 | (1) | 394,903 | 394,903 | ||||||
Camilla Sylvest | 703 | (1) | 394,903 | 394,903 | ||||||
96 | ||
2021 | 2022 | 2023 | 2024 | 2025 | ||||||||
Base pay of the CEO (EUR) | € | 551,250 | 606,368 | 606,368 | 700,000 | 732,000 | ||||||
Base pay of the CEO (USD) | $ | 580,825 | 638,901 | 655,787 | 757,680 | 827,160 | ||||||
Non-equity remuneration of the CEO (USD) (base pay, short-term cash incentive, pension contributions and other compensation elements) | $ | 1,285,136 | 1,443,925 | 1,285,056 | 1,598,471 | 1,631,826 | ||||||
Total remuneration of the CEO (USD) (non-equity remuneration, STI and LTI) | $ | 7,263,828 | 7,778,298 | 11,944,8351) | 7,807,786 | 7,429,771 | ||||||
Non-equity median salary paid to employees (USD) | $ | 157,349 | 153,193 | 159,500 | 180,543 | 195,500 | ||||||
Non-equity remuneration ratio employee/CEO | 12% | 11% | 12% | 11% | 12% | |||||||
Average remuneration paid to Non-Executive Director (USD) | $ | 54,484 | 48,587 | 59,230 | 81,204 | 85,992 | ||||||
Number of employees on December 31 | 650 | 843 | 1,148 | 1,599 | 1,863 | |||||||
Share price at end of year Euronext (EUR) on December 31 | € | 315.30 | 348.30 | 343.50 | 600.00 | 716.80 | ||||||
Share price at end of year Euronext (USD) on December 31 | $ | 357.11 | 371.50 | 379.57 | 623.34 | 842.24 |
Ratio of non-equity compensation of the median employee compared to the CEO for the year ended December 31, 2025 | ||
All employees | 12% | |
North American employees | 16% | |
European employees | 9% | |
Japanese employees | 5% | |
Rest of the World employees | 13% | |
97 | ||
Total employment costs in the year ended December 31, 2025 | ||
(in millions of $) | ||
North-America | 272 | |
Europe | 247 | |
Japan | 16 | |
Rest of the World | 3 | |
2021 | 2022 | 2023 | 2024 | 2025 | ||||||
Stock options granted to the CEO | 25,000 | 25,000 | 30,000 | 18,279 | 15,027 | |||||
RSUs granted to the CEO | 5,700 | 5,700 | 6,700 | 6,762 | 0 | |||||
PSUs granted to the CEO | N/A | N/A | N/A | N/A | 5,085 | |||||
Median stock options granted to employees | 981 | 900 | 600 | 306 | 221 | |||||
Median RSUs granted to employees | 200 | 200 | 94 | 148 | 75 | |||||
Ratio employee/CEO for stock options | 4% | 4% | 2% | 2% | 1% | |||||
Ratio employee/CEO for RSUs1) | 4% | 4% | 1% | 2% | N/A | |||||
Ratio employee RSUs/CEO for PSUs1) | N/A | N/A | N/A | N/A | 1% | |||||
Median number of stock options granted to Non-Executive Directors2) | 2,700 | 2,700 | 1,600 | N/A | N/A | |||||
Median number of RSUs granted to Non-Executive Directors | 600 | 600 | 350 | 1,124 | 703 | |||||
Median stock options granted to employees | 981 | 900 | 600 | 306 | 120 | |||||
Ratio Non-Executive Directors/employee stock options2) | 36% | 33% | 38% | N/A | N/A | |||||
Ratio Non-Executive Directors/employee RSUs | 33% | 33% | 27% | 13% | 11% |
98 | ||
99 | ||
(in $) | Base pay1) | Base pay in % change vs the prior year1) | Sign on bonus | Corporate bonus2) | Variable short-term incentive | Variable cash as % of target opportunity | Compensation in the form of stock options3) | Compensation in the form of RSUs | Compensation in the form of PSUs | Pension benefits4) | Fringe benefits5) | Other benefits6) | % fixed (of total)7) | Total | ||||||||||||||
CEO - Tim Van Hauwermeiren8) 11) | ||||||||||||||||||||||||||||
2025 | 827,160 | 5% | — | — | 744,444 | 60% | 2,941,497 | — | 2,856,448 | 44,168 | 16,054 | — | 12% | 7,429,771 | ||||||||||||||
2024 | 757,680 | 15% | — | — | 795,563 | 60% | 3,194,813 | 3,014,500 | — | 29,118 | 16,112 | — | 10% | 7,807,786 | ||||||||||||||
2023 | 655,787 | —% | — | — | 590,215 | 60% | 8,084,605 | 2,575,174 | — | 22,821 | 16,233 | — | 6% | 11,944,835 | ||||||||||||||
CFO - Karl Gubitz | ||||||||||||||||||||||||||||
2025 | 578,000 | 5% | — | 4,690 | 346,800 | 40% | 1,562,679 | — | 1,675,670 | 21,000 | 46,514 | 3,466 | 15% | 4,238,819 | ||||||||||||||
2024 | 553,000 | 7% | — | 3,636 | 331,800 | 40% | 2,018,973 | 2,100,610 | — | 13,800 | 40,832 | 205,939 | 15% | 5,268,590 | ||||||||||||||
2023 | 516,043 | 6% | — | 3,556 | 260,866 | 40% | 2,626,062 | 1,287,587 | — | 11,600 | 30,597 | 20,601 | 12% | 4,756,913 | ||||||||||||||
COO - Karen Massey9) 12) | ||||||||||||||||||||||||||||
2025 | 741,641 | 4% | — | 4,708 | 648,936 | 50% | 1,792,860 | — | 1,922,836 | 181,337 | 184,738 | 843,989 | 31% | 6,321,045 | ||||||||||||||
2024 | 655,657 | 37% | — | 3,636 | 573,593 | 50% | 2,018,973 | 2,100,610 | — | 165,394 | 57,348 | 619,272 | 24% | 6,194,483 | ||||||||||||||
2023 | 481,471 | N/A | 338,000 | 2,921 | 467,662 | 50% | 3,939,093 | 2,296,517 | — | 56,550 | 35,100 | 35,743 | 8% | 7,653,057 | ||||||||||||||
COO - Keith Woods10) | ||||||||||||||||||||||||||||
2023 | 305,022 | (48)% | — | — | — | —% | — | — | — | 11,600 | 34,434 | — | 100% | 351,056 | ||||||||||||||
100 | ||
Information regarding the reported financial year | ||||||||||||||||||||||||||||||||
Opening Balance | During the Year | Closing balance | ||||||||||||||||||||||||||||||
Name of Directors, Position | Specification plan | Performance Period | Award Date | Vesting date | End of retention period | Exercise Period | Exercise price of stock option (€) | Stock options held at the beginning of the period | Stock options awarded | Stock options exercised | Stock options forfeited | Stock options vested | Stock options subjected to a service period | Stock options awarded and unvested | Stock options held at the end of the year | Stock options subjected to a retention period | ||||||||||||||||
Tim Van Hauwermeiren, CEO | Equity incentive plan | 21/12/2018 - 01/12/2021 | 21/12/2018 | (1) | 31/12/2021 | 01/01/2022 - 21/12/2028 | 86.32 | 80,000 | — | — | — | — | — | — | 80,000 | — | ||||||||||||||||
20/12/2019 - 01/12/2022 | 20/12/2019 | (1) | 31/12/2022 | 01/01/2023 - 20/12/2029 | 135.75 | 80,000 | — | — | — | — | — | — | 80,000 | — | ||||||||||||||||||
21/12/2020 - 01/12/2023 | 21/12/2020 | (1) | 31/12/2023 | 01/01/2024 - 21/12/2030 | 247.60 | 50,000 | — | — | — | — | — | — | 50,000 | — | ||||||||||||||||||
24/12/2021 - 01/12/2024 | 24/12/2021 | (1) | 31/12/2024 | 01/01/2025 - 24/12/2031 | 309.20 | 25,000 | — | — | — | — | — | — | 25,000 | — | ||||||||||||||||||
23/12/2022 - 01/12/2025 | 23/12/2022 | (1) | 31/12/2025 | 01/01/2026 - 23/12/2032 | 359.60 | 25,000 | — | — | — | 8,333 | — | — | 25,000 | — | ||||||||||||||||||
03/07/2023 - 01/07/2026 | 03/07/2023 | (1) | 31/12/2026 | 01/01/2027 - 03/07/2033 | 355.40 | 30,000 | — | — | — | 10,000 | 5,833 | 5,833 | 30,000 | 30,000 | ||||||||||||||||||
28/06/2024 - 01/06/2027 | 28/06/2024 | (1) | 31/12/2027 | 01/01/2028 - 28/06/2034 | 416.40 | 18,279 | — | — | — | 9,139 | 9,140 | 9,140 | 18,279 | 18,279 | ||||||||||||||||||
30/06/2025 - 01/06/2028 | 30/06/2025 | (1) | 31/12/2028 | 01/01/2029 - 30/06/2035 | 479.30 | — | 15,027 | — | — | — | 15,027 | 15,027 | 15,027 | 15,027 | ||||||||||||||||||
Total | 308,279 | 15,027 | — | — | 27,472 | 30,000 | 30,000 | 323,306 | 63,306 | |||||||||||||||||||||||
Karl Gubitz, CFO | Equity incentive plan | 01/07/2021 - 01/07/2024 | 01/07/2021 | (1) | N/A | 01/07/2022 - 01/07/2031 | 255.10 | 24,000 | — | 24,000 | — | — | — | — | — | — | ||||||||||||||||
01/07/2022 - 01/07/2025 | 01/07/2022 | (1) | N/A | 01/07/2023 - 01/07/2032 | 357.50 | 16,000 | — | — | — | 3,111 | — | — | 16,000 | — | ||||||||||||||||||
03/07/2023 - 01/07/2026 | 03/07/2023 | (1) | N/A | 03/07/2024 - 03/07/2033 | 355.40 | 15,000 | — | — | — | 5,000 | 2,917 | 2,917 | 15,000 | — | ||||||||||||||||||
28/06/2024 - 01/06/2027 | 28/06/2024 | (1) | N/A | 28/06/2025 - 28/06/2034 | 416.40 | 12,738 | — | — | — | 6,369 | 6,369 | 6,369 | 12,738 | — | ||||||||||||||||||
30/06/2025 - 01/06/2028 | 30/06/2025 | (1) | N/A | 01/01/2029 - 30/06/2035 | 479.30 | — | 8,812 | — | — | — | 8,812 | 8,812 | 8,812 | — | ||||||||||||||||||
Total | 67,738 | 8,812 | 24,000 | — | 14,480 | 18,098 | 18,098 | 52,550 | — | |||||||||||||||||||||||
Karen Massey, COO | Equity incentive plan | 03/07/2023 - 01/07/2026 | 03/07/2023 | (1) | N/A | 03/07/2024 - 03/07/2033 | 355.40 | 22,500 | — | 12,000 | — | 7,500 | 4,375 | 4,375 | 10,500 | — | ||||||||||||||||
28/06/2024 - 01/06/2027 | 28/06/2024 | (1) | N/A | 28/06/2025 - 28/06/2034 | 416.40 | 12,738 | — | — | — | 6,369 | 6,369 | 6,369 | 12,738 | — | ||||||||||||||||||
30/06/2025 - 01/06/2028 | 30/06/2025 | (1) | N/A | 01/01/2029 - 30/06/2035 | 479.30 | — | 10,110 | — | — | — | 10,110 | 10,110 | 10,110 | — | ||||||||||||||||||
Total | 35,238 | 10,110 | 12,000 | — | 13,869 | 20,854 | 20,854 | 33,348 | 3 3 , 3 4 8 | — | ||||||||||||||||||||||
101 | ||
Information regarding the reported financial year | ||||||||||||||||||||||||
The main conditions of PSU plan | Opening balance | During the Year | Closing balance | |||||||||||||||||||||
Name of Directors, Position | Vesting period | Award Date | Vesting date | End of retention period | PSUs held at the beginning of the year | PSUs awarded | PSU Forfeited | PSUs vested | PSUs subject to a service condition | PSUs awarded and unvested | PSUs held at the closing of the year | PSUs subject to a retention period | ||||||||||||
Tim van Hauwermeiren, CEO | 01/01/2025 - 31/12/2027 | 30/06/2025 | 31/12/2027 | N/A | – | 5,085 | – | – | – | 5,085 | 5,085 | – | ||||||||||||
Total | – | 5,085 | – | – | – | 5,085 | 5,085 | – | ||||||||||||||||
Karl Gubitz, CFO | 01/01/2025 - 31/12/2027 | 30/06/2025 | 31/12/2027 | N/A | – | 2,983 | – | – | – | 2,983 | 2,983 | – | ||||||||||||
Total | – | 2,983 | – | – | – | 2,983 | 2,983 | – | ||||||||||||||||
Karen Massey, COO | 01/01/2025 - 31/12/2027 | 30/06/2025 | 31/12/2027 | N/A | – | 3,423 | – | – | – | 3,423 | 3,423 | – | ||||||||||||
Total | – | 3,423 | – | – | – | 3,423 | 3,423 | – | ||||||||||||||||
102 | ||
Information regarding the reported financial year | ||||||||||||||||||||||||
The main conditions of RSU plan | Opening balance | During the Year | Closing balance | |||||||||||||||||||||
Name of Directors, Position | Vesting period | Award Date | Vesting date | End of retention period | RSUs held at the beginning of the year | RSUs awarded | RSU Forfeited | RSUs vested | RSUs subject to a service condition | RSUs awarded and unvested | RSUs held at the closing of the year | RSUs subject to a retention period | ||||||||||||
Tim van Hauwermeiren, CEO | 24/12/2021 - 24/12/2025 | 24/12/2021 | (1) | N/A | 1,425 | — | — | 1,425 | — | — | — | — | ||||||||||||
23/12/2022 - 23/12/2026 | 23/12/2022 | (1) | N/A | 2,850 | — | — | 1,425 | — | 1,425 | 1,425 | — | |||||||||||||
03/07/2023 - 03/07/2027 | 07/03/2023 | (1) | N/A | 5,025 | — | — | 1,675 | — | 3,350 | 3,350 | — | |||||||||||||
28/06/2024 - 28/06/2028 | 28/06/2024 | (1) | N/A | 6,762 | — | — | 1,690 | — | 5,072 | 5,072 | — | |||||||||||||
Total | 16,062 | — | — | 6,215 | — | 9,847 | 9,847 | — | ||||||||||||||||
Karl Gubitz, CFO | 01/07/2021 - 01/07/2025 | 01/07/2021 | (1) | N/A | 1,350 | — | — | 1,350 | — | — | — | — | ||||||||||||
01/07/2022 - 01/07/2026 | 01/07/2022 | (1) | N/A | 1,800 | — | — | 900 | — | 900 | 900 | — | |||||||||||||
03/07/2023 - 03/07/2027 | 03/07/2023 | (1) | N/A | 2,513 | — | — | 838 | — | 1,675 | 1,675 | — | |||||||||||||
28/06/2024 - 28/06/2028 | 28/06/2024 | (1) | N/A | 4,712 | — | — | 1,178 | — | 3,534 | 3,534 | — | |||||||||||||
Total | 10,375 | — | — | 4,266 | — | 6,109 | 6,109 | — | ||||||||||||||||
Karen Massey, COO | 03/07/2023 - 03/07/2027 | 07/03/2023 | (1) | N/A | 3,769 | — | — | 1,256 | — | 2,513 | 2,513 | — | ||||||||||||
28/06/2024 - 28/06/2028 | 28/06/2024 | (1) | N/A | 4,712 | — | — | 1,178 | — | 3,534 | 3,534 | — | |||||||||||||
Total | 8,481 | — | — | 2,434 | — | 6,047 | 6,047 | — | ||||||||||||||||
103 | ||
(in $) | Compensation | |
Base pay | 3,138,512 | |
Variable STI1) | 1,526,247 | |
Compensation in the form of stock options | 10,521,797 | |
Compensation in the form of PSUs | 7,443,617 | |
Pension benefits2) | 80,045 | |
Fringe benefits3) | 107,679 | |
Other benefits4) | 3,187,985 | |
Total | 26,005,882 |
104 | ||
PSUs granted in 2025 | Stock options granted in 2025 | |||||||||||
Name | # PSUs | Key terms | # Stock options | Exercise price in € | Exercise price in $ | Key terms | ||||||
Arjen Lemmen | 3,423 | PSUs are subject to a cliff vest and settlement at the end of a performance period of 3-years. | 10,110 | 479.30 | 561.74 | 1/3 vests after year 1 2/3 vest in monthly installments in year 2 and 3. | ||||||
Malini Moorthy | 2,983 | 8,812 | 479.30 | 561.74 | ||||||||
Luc Truyen | 2,983 | 8,812 | 479.30 | 561.74 | ||||||||
Peter Ulrichts | 2,983 | 8,812 | 479.30 | 561.74 | ||||||||
Andria Wilk | 879 | 2,596 | 479.30 | 561.74 | ||||||||
105 | ||
Information regarding the reported financial year | ||||||||||||||||||||||||
Opening balance | During the Year | Closing balance | ||||||||||||||||||||||
Name of Directors, Position | Specification plan | Performance period | Award date | Vesting date | Exercise period | Exercise price of stock option in € | Stock options held at the beginning of the year | Stock options awarded | Stock options exercised | Stock options forfeited | Stock options vested | Stock options held at the end of the year | ||||||||||||
Arjen Lemmen, Vice President of Corporate Development & Strategy | Equity incentive plan | 21/12/2020 - 01/12/2023 | 21/12/2020 | (1) | 01/01/2024 - 21/12/2030 | 247.60 | 47,674 | — | 32,674 | — | — | 15,000 | ||||||||||||
24/12/2021 - 01/12/2024 | 24/12/2021 | (1) | 01/01/2025 - 24/12/2031 | 309.20 | 16,000 | — | — | — | — | 16,000 | ||||||||||||||
23/12/2022 - 01/12/2025 | 23/12/2022 | (1) | 23/12/2023 - 23/12/2032 | 359.60 | 16,000 | — | — | — | 5,333 | 16,000 | ||||||||||||||
03/07/2023 - 01/07/2026 | 03/07/2023 | (1) | 03/07/2024 - 03/07/2033 | 355.40 | 15,000 | — | — | — | 5,000 | 15,000 | ||||||||||||||
28/06/2024 - 01/06/2027 | 28/06/2024 | (1) | 01/01/2028 - 28/06/2034 | 416.40 | 12,738 | — | — | — | 6,369 | 12,738 | ||||||||||||||
30/06/2025 - 01/06/2028 | 30/06/2025 | (1) | 01/01/2029 - 30/06/2035 | 479.30 | — | 10,110 | — | — | — | 10,110 | ||||||||||||||
Total | 107,412 | 10,110 | 32,674 | — | 16,702 | 84,848 | ||||||||||||||||||
Malini Moorthy, Legal Counsel | Equity incentive plan | 01/04/2022 - 01/04/2025 | 01/04/2022 | (1) | 01/04/2023 - 01/04/2032 | 282.50 | 6,500 | — | 6,500 | — | 2,667 | — | ||||||||||||
03/07/2023 - 01/07/2026 | 03/07/2023 | (1) | 03/07/2024 - 03/07/2033 | 355.40 | 15,000 | — | 5,000 | — | 5,000 | 10,000 | ||||||||||||||
28/06/2024 - 01/06/2027 | 28/06/2024 | (1) | 01/01/2028 - 28/06/2034 | 416.40 | 12,738 | — | — | — | 6,369 | 12,738 | ||||||||||||||
30/06/2025 - 01/06/2028 | 30/06/2025 | (1) | 01/01/2029 - 30/06/2035 | 479.30 | — | 8,812 | — | — | — | 8,812 | ||||||||||||||
Total | 34,238 | 8,812 | 11,500 | — | 14,036 | 31,550 | ||||||||||||||||||
Luc Truyen, CMO | Equity incentive plan | 01/10/2021 - 01/10/2024 | 01/10/2021 | (1) | 01/01/2025 - 01/10/2026 | 259.5 | 24,000 | — | 24,000 | — | — | — | ||||||||||||
23/12/2022 - 01/12/2025 | 23/12/2022 | (1) | 01/01/2026 - 23/12/2027 | 359.6 | 16,000 | — | — | — | 5,333 | 16,000 | ||||||||||||||
03/07/2023 - 01/07/2026 | 03/07/2023 | (1) | 01/01/2027 - 03/07/2028 | 355.4 | 15,000 | — | — | — | 5,000 | 15,000 | ||||||||||||||
28/06/2024 - 01/06/2027 | 28/06/2024 | (1) | 01/01/2028 - 28/06/2034 | 416.40 | 12,738 | — | — | — | 6,369 | 12,738 | ||||||||||||||
30/06/2025 - 01/06/2028 | 30/06/2025 | (1) | 01/01/2029 - 30/06/2035 | 479.30 | — | 8,812 | — | — | — | 8,812 | ||||||||||||||
Total | 67,738 | 8,812 | 24,000 | — | 16,702 | 52,550 | ||||||||||||||||||
Peter Ulrichts, CSO | Equity incentive plan | 20/12/2019 - 01/12/2022 | 20/12/2019 | (1) | 01/01/2023 - 20/12/2029 | 135.75 | 4,000 | — | 4,000 | — | — | — | ||||||||||||
21/12/2020 - 01/12/2023 | 21/12/2020 | (1) | 01/01/2024 - 21/12/2030 | 247.60 | 7,651 | — | 7,651 | — | — | — | ||||||||||||||
24/12/2021 - 01/12/2024 | 24/12/2021 | (1) | 01/01/2025 - 24/12/2026 | 309.20 | 3,420 | — | 3,420 | — | — | — | ||||||||||||||
23/12/2022 - 01/12/2025 | 23/12/2022 | (1) | 01/01/2026 - 23/12/2027 | 359.60 | 16,000 | — | — | — | 3,811 | 16,000 | ||||||||||||||
03/07/2023 - 01/07/2026 | 03/07/2023 | (1) | 01/01/2027 - 03/07/2028 | 355.40 | 15,000 | — | — | — | 5,000 | 15,000 | ||||||||||||||
28/06/2024 - 01/06/2027 | 28/06/2024 | (1) | 01/01/2028 - 28/06/2034 | 416.40 | 12,738 | — | — | — | 4,978 | 12,738 | ||||||||||||||
30/06/2025 - 01/06/2028 | 30/06/2025 | (1) | 01/01/2029 - 30/06/2035 | 479.30 | — | 8,812 | — | — | 1,039 | 8,812 | ||||||||||||||
Total | 58,809 | 8,812 | 15,071 | — | 14,828 | 52,550 | ||||||||||||||||||
Andria Wilk, Global Head of Quality | Equity incentive plan | 21/12/2020 - 01/12/2023 | 21/12/2020 | (1) | 01/01/2024 - 21/12/2025 | 247.60 | 87 | — | 87 | — | — | — | ||||||||||||
24/12/2021 - 01/12/2024 | 24/12/2021 | (1) | 01/01/2025 - 24/12/2031 | 309.20 | 4,446 | — | 1,167 | — | — | 3,279 | ||||||||||||||
23/12/2022 - 01/12/2025 | 23/12/2022 | (1) | 01/01/2026 - 23/12/2027 | 359.60 | 4,600 | — | — | — | 1,126 | 4,600 | ||||||||||||||
03/07/2023 - 01/07/2026 | 03/07/2023 | (1) | 01/01/2027 - 03/07/2033 | 355.40 | 4,600 | — | — | — | 1,276 | 4,600 | ||||||||||||||
28/06/2024 - 01/06/2027 | 28/06/2024 | (1) | 01/01/2028 - 28/06/2034 | 416.40 | 3,599 | — | — | — | 1,406 | 3,599 | ||||||||||||||
30/06/2025 - 01/06/2028 | 30/06/2025 | (1) | 01/01/2029 - 30/06/2035 | 479.30 | — | 2,596 | — | — | 306 | 2,596 | ||||||||||||||
Total | 17,332 | 2,596 | 1,254 | — | 4,114 | 18,674 | ||||||||||||||||||
106 | ||
Information regarding the reported financial year | ||||||||||||||||
Main conditions of the PSU plan | Opening balance | During the Year | Closing balance | |||||||||||||
Name of Directors, Position | Performance period | Award date | Vesting date | PSU’s held at the beginning of the year | PSUs awarded | PSUs forfeited | PSUs vested | PSUs held at the closing of the year | ||||||||
Arjen Lemmen, Vice President of Corporate Development & Strategy | 01/01/2025 - 31/12/2027 | 30/06/2025 | 31/12/2027 | — | 3,423 | — | — | 3,423 | ||||||||
Total | — | 3,423 | — | — | 3,423 | |||||||||||
Malini Moorthy, General Counsel and Corporate Secretary | 01/01/2025 - 31/12/2027 | 30/6/2025 | 31/12/2027 | — | 2,983 | — | — | 2,983 | ||||||||
Total | — | 2,983 | — | — | 2,983 | |||||||||||
Luc Truyen, CMO | 01/01/2025 - 31/12/2027 | 30/6/2025 | 31/12/2027 | — | 2,983 | — | — | 2,983 | ||||||||
Total | — | 2,983 | — | — | 2,983 | |||||||||||
Peter Ulrichts, CSO | 01/01/2025 - 31/12/2027 | 30/6/2025 | 31/12/2027 | — | 2,983 | — | — | 2,983 | ||||||||
Total | — | 2,983 | — | — | 2,983 | |||||||||||
Andria Wilk, Global Head of Quality | 01/01/2025 - 31/12/2027 | 30/6/2025 | 31/12/2027 | — | 879 | — | — | 879 | ||||||||
Total | — | 879 | — | — | 879 | |||||||||||
107 | ||
Information regarding the reported financial year | ||||||||||||||||
The main conditions of the RSU plan | Opening balance | During the Year | Closing balance | |||||||||||||
Name of Directors, Position | Vesting period | Award date | Vesting date | RSU’s held at the beginning of the year | RSUs awarded | RSUs forfeited | RSUs vested | RSUs held at the closing of the year | ||||||||
Arjen Lemmen, Vice President of Corporate Development & Strategy | 24/12/2021 - 24/12/2025 | 24/12/2021 | (1) | 900 | — | — | 900 | — | ||||||||
23/12/2022 - 23/12/2026 | 23/12/2022 | (1) | 1,800 | — | — | 900 | 900 | |||||||||
03/07/2023 - 03/07/2027 | 03/07/2023 | (1) | 2,513 | — | — | 838 | 1,675 | |||||||||
28/06/2024 - 27/06/2028 | 28/06/2024 | (1) | 4,712 | — | — | 1,178 | 3,534 | |||||||||
Total | 9,925 | — | — | 3,816 | 6,109 | |||||||||||
Malini Moorthy, General Counsel and Corporate Secretary | 01/04/2022 - 01/04/2026 | 01/04/2022 | (1) | 2,700 | — | — | 1,350 | 1,350 | ||||||||
03/07/2023 - 03/07/2027 | 03/07/2023 | (1) | 2,513 | — | — | 838 | 1,675 | |||||||||
28/06/2024 - 27/06/2028 | 28/06/2024 | (1) | 4,712 | — | — | 1,178 | 3,534 | |||||||||
Total | 9,925 | — | — | 3,366 | 6,559 | |||||||||||
Luc Truyen, CMO | 01/10/2021 - 01/10/2025 | 01/10/2021 | (1) | 1,350 | — | — | 1,350 | — | ||||||||
23/12/2022 - 23/12/2026 | 23/12/2022 | (1) | 1,800 | — | — | 900 | 900 | |||||||||
03/07/2023 - 03/07/2027 | 03/07/2023 | (1) | 2,513 | — | — | 838 | 1,675 | |||||||||
28/06/2024 - 27/06/2028 | 28/06/2024 | (1) | 4,712 | — | — | 1,178 | 3,534 | |||||||||
Total | 10,375 | — | — | 4,266 | 6,109 | |||||||||||
Peter Ulrichts, CSO | 24/12/2021 - 24/12/2025 | 24/12/2021 | (1) | 190 | — | — | 190 | — | ||||||||
23/12/2022 - 23/12/2026 | 23/12/2022 | (1) | 1,800 | — | — | 900 | 900 | |||||||||
03/07/2023 - 03/07/2027 | 03/07/2023 | (1) | 2,513 | — | — | 838 | 1,675 | |||||||||
28/06/2024 - 27/06/2028 | 28/06/2024 | (1) | 4,712 | — | — | 1,178 | 3,534 | |||||||||
Total | 9,215 | — | — | 3,106 | 6,109 | |||||||||||
Andria Wilk, Global Head of Quality | 24/12/2021 - 24/12/2025 | 24/12/2021 | (1) | 247 | — | — | 247 | — | ||||||||
23/12/2022 - 23/12/2026 | 23/12/2022 | (1) | 500 | — | — | 250 | 250 | |||||||||
03/07/2023 - 03/07/2027 | 03/07/2023 | (1) | 750 | — | — | 250 | 500 | |||||||||
28/06/2024 - 27/06/2028 | 28/06/2024 | (1) | 1,331 | — | — | 333 | 998 | |||||||||
Total | 2,828 | — | — | 1,080 | 1,748 | |||||||||||
108 | ||
Information regarding the reported financial year | ||||||||||||||||||||
The main conditions of RSU plan | Opening balance | During the Year | Closing balance | |||||||||||||||||
Name of member of Board of Directors | Vesting period | Award date | Vesting date | End of holding period | RSUs held at the beginning of the year | RSUs awarded | RSUs vested | RSUs subject to a service condition | RSUs awarded and unvested | RSUs held at the closing of the year | ||||||||||
Ana Céspedes | 23/12/2022 - 23/12/2026 | 23/12/2022 | (1) | N/A | 450 | — | 225 | — | 225 | 225 | ||||||||||
03/07/2023 - 03/07/2027 | 03/07/2023 | (1) | N/A | 131 | — | 43 | — | 88 | 88 | |||||||||||
28/06/2024 - 28/06/2025 | 28/06/2024 | (1) | 28/06/2028 | 1,065 | — | 1,065 | — | — | 1,065 | |||||||||||
30/06/2025 - 30/06/2026 | 30/06/2025 | (1) | 30/06/2029 | — | 703 | — | — | 703 | 703 | |||||||||||
Total | 1,646 | 703 | 1,333 | — | 1,016 | 2,081 | ||||||||||||||
James Daly | 24/12/2021 - 24/12/2025 | 24/12/2021 | (1) | N/A | 150 | — | 150 | — | — | — | ||||||||||
23/12/2022 - 23/12/2026 | 23/12/2022 | (1) | N/A | 300 | — | 150 | — | 150 | 150 | |||||||||||
03/07/2023 - 03/07/2027 | 03/07/2023 | (1) | N/A | 263 | — | 88 | — | 175 | 175 | |||||||||||
28/06/2024 - 28/06/2025 | 28/06/2024 | (1) | 28/06/2028 | 1,065 | — | 1,065 | — | — | 1,065 | |||||||||||
30/06/2025 - 30/06/2026 | 30/06/2025 | (1) | 30/06/2029 | — | 703 | — | — | 703 | 703 | |||||||||||
Total | 1,778 | 703 | 1,453 | — | 1,028 | 2,093 | ||||||||||||||
Donald deBethizy2) | 24/12/2021 - 24/12/2025 | 24/12/2021 | (1) | N/A | 150 | — | 150 | — | — | — | ||||||||||
23/12/2022 - 23/12/2026 | 23/12/2022 | (1) | N/A | 300 | — | 150 | — | 150 | 150 | |||||||||||
03/07/2023 - 03/07/2027 | 03/07/2023 | (1) | N/A | 263 | — | 263 | — | — | — | |||||||||||
28/06/2024 - 28/06/2025 | 28/06/2024 | (1) | 28/06/2028 | 1,065 | — | 1,065 | — | — | 1,065 | |||||||||||
Total | 1,778 | — | 1,628 | — | 150 | 1,215 | ||||||||||||||
Pamela Klein | 24/12/2021 - 24/12/2025 | 24/12/2021 | (1) | N/A | 300 | — | 150 | — | 150 | 150 | ||||||||||
23/12/2022 - 23/12/2026 | 23/12/2022 | (1) | N/A | 450 | — | 150 | — | 300 | 300 | |||||||||||
03/07/2023 - 03/07/2027 | 03/07/2023 | (1) | N/A | 350 | — | 87 | — | 263 | 263 | |||||||||||
28/06/2024 - 28/06/2025 | 28/06/2024 | (1) | 28/06/2028 | 1,065 | — | 1,065 | — | — | 1,065 | |||||||||||
30/06/2025 - 30/06/2026 | 30/06/2025 | (1) | 30/06/2029 | — | 703 | — | — | 703 | 703 | |||||||||||
Total | 2,165 | 703 | 1,452 | — | 1,416 | 2,481 | ||||||||||||||
Brian Kotzin | 28/06/2024 - 28/06/2028 | 28/06/2024 | (1) | 28/06/2028 | 1,598 | — | 1,598 | — | — | 1,598 | ||||||||||
30/06/2025 - 30/06/2026 | 30/06/2025 | (1) | 30/06/2029 | — | 703 | — | — | 703 | 703 | |||||||||||
Total | 1,598 | 703 | 1,598 | — | 703 | 2,301 | ||||||||||||||
109 | ||
Information regarding the reported financial year | ||||||||||||||||||||
The main conditions of RSU plan | Opening balance | During the Year | Closing balance | |||||||||||||||||
Steve Krognes | 03/04/2023 - 03/04/2027 | 03/04/2023 | (1) | N/A | 394 | — | 132 | — | 262 | 262 | ||||||||||
28/06/2024 - 28/06/2025 | 28/06/2024 | (1) | 28/06/2028 | 1,065 | — | 1,065 | — | — | 1,065 | |||||||||||
30/06/2025 - 30/06/2026 | 30/06/2025 | (1) | 30/06/2029 | — | 703 | — | — | 703 | 703 | |||||||||||
Total | 1,459 | 703 | 1,197 | — | 965 | 2,030 | ||||||||||||||
Anthony Rosenberg | 24/12/2021 - 24/12/2025 | 24/12/2021 | (1) | N/A | 150 | — | 150 | — | — | — | ||||||||||
23/12/2022 - 23/12/2026 | 23/12/2022 | (1) | N/A | 300 | — | 150 | — | 150 | 150 | |||||||||||
03/07/2023 - 03/07/2027 | 03/07/2023 | (1) | N/A | 263 | — | 88 | — | 175 | 175 | |||||||||||
28/06/2024 - 28/06/2025 | 28/06/2024 | (1) | 28/06/2028 | 1,065 | — | 1,065 | — | — | 1,065 | |||||||||||
30/06/2025 - 30/06/2026 | 30/06/2025 | (1) | 30/06/2029 | — | 703 | — | — | 703 | 703 | |||||||||||
Total | 1,778 | 703 | 1,453 | — | 1,028 | 2,093 | ||||||||||||||
Camilla Sylvest | 03/10/2022 - 03/10/2026 | 03/10/2022 | (1) | N/A | 450 | — | 225 | — | 225 | 225 | ||||||||||
03/07/2023 - 03/07/2027 | 03/07/2023 | (1) | N/A | 197 | — | 65 | — | 132 | 132 | |||||||||||
28/06/2024 - 28/06/2025 | 28/06/2024 | (1) | 28/06/2028 | 1,065 | — | 1,065 | — | — | 1,065 | |||||||||||
30/06/2025 - 30/06/2026 | 30/06/2025 | (1) | 30/06/2029 | — | 703 | — | — | 703 | 703 | |||||||||||
Total | 1,712 | 703 | 1,355 | — | 1,060 | 2,125 | ||||||||||||||
Peter Verhaeghe | 24/12/2021 - 24/12/2025 | 24/12/2021 | (1) | N/A | 150 | — | 150 | — | — | — | ||||||||||
23/12/2022 - 23/12/2026 | 23/12/2022 | (1) | N/A | 300 | — | 150 | — | 150 | 150 | |||||||||||
03/07/2023 - 03/07/2027 | 03/07/2023 | (1) | N/A | 263 | — | 88 | — | 175 | 175 | |||||||||||
28/06/2024 - 28/06/2025 | 28/06/2024 | (1) | 28/06/2028 | 1,065 | — | 1,065 | — | — | 1,065 | |||||||||||
30/06/2025 - 30/06/2026 | 30/06/2025 | (1) | 30/06/2029 | — | 703 | — | — | 703 | 703 | |||||||||||
Total | 1,778 | 703 | 1,453 | — | 1,028 | 2,093 | ||||||||||||||
110 | ||
Information regarding the reported financial year | ||||||||||||||||||||||||||||
Opening balance | During the Year | Closing balance | ||||||||||||||||||||||||||
Name of Directors | Performance period | Award date | Vesting date | End of retention period | Exercise period | Exercise price of stock option (€) | Stock options held at the beginning of the year | Stock options awarded | Stock options exercised | Stock options vested | Stock options subject to a service condition | Stock options awarded and unvested | Stock options held at the end of the year | Stock options subject to a retention period | ||||||||||||||
Ana Céspedes | 23/12/2022 - 23/12/2025 | 23/12/2022 | (2) | 31/12/2025 | 23/12/2023 - 23/12/2032 | 359.60 | 4,050 | — | — | 4,050 | — | — | 4,050 | — | ||||||||||||||
03/07/2023 - 03/07/2026 | 03/07/2023 | (2) | 31/12/2026 | 03/07/2024 - 03/07/2033 | 355.40 | 800 | — | — | — | — | 800 | 800 | 800 | |||||||||||||||
Total | 4,850 | — | — | 4,050 | — | 800 | 4,850 | 800 | ||||||||||||||||||||
James Daly | 21/12/2020 - 21/12/2023 | 21/12/2020 | (1) | N/A | 21/12/2021 - 21/12/2030 | 247.60 | 10,000 | — | 10,000 | — | — | — | — | — | ||||||||||||||
24/12/2021 - 24/12/2024 | 24/12/2021 | (2) | 31/12/2024 | 24/12/2022 - 24/12/2031 | 309.20 | 2,700 | — | 2,700 | — | — | — | — | — | |||||||||||||||
23/12/2022 - 23/12/2025 | 23/12/2022 | (2) | 31/12/2025 | 23/12/2023 - 23/12/2032 | 359.60 | 2,700 | — | 2,700 | — | — | — | 2,700 | — | |||||||||||||||
03/07/2023 - 03/07/2026 | 03/07/2023 | (2) | 31/12/2026 | 03/07/2024 - 03/07/2033 | 355.40 | 1,600 | — | — | — | — | 1,600 | 1,600 | 1,600 | |||||||||||||||
Total | 17,000 | — | 15,400 | — | — | 1,600 | 4,300 | 1,600 | ||||||||||||||||||||
Donald deBethizy 3) | 18/06/2016 - 18/06/2019 | 18/06/2016 | (1) | N/A | 18/06/2017 - 18/06/2026 | 11.38 | 10,000 | — | — | — | — | — | 10,000 | — | ||||||||||||||
21/12/2018 - 21/12/2021 | 21/12/2018 | (1) | N/A | 21/12/2019 - 21/12/2028 | 86.32 | 10,000 | — | — | — | — | — | 10,000 | — | |||||||||||||||
20/12/2019 - 20/12/2022 | 20/12/2019 | (1) | N/A | 20/12/2020 - 20/12/2029 | 135.75 | 10,000 | — | — | — | — | — | 10,000 | — | |||||||||||||||
21/12/2020 - 21/12/2023 | 21/12/2020 | (1) | N/A | 21/12/2021 - 21/12/2030 | 247.60 | 10,000 | — | — | — | — | — | 10,000 | — | |||||||||||||||
24/12/2021 - 24/12/2024 | 24/12/2021 | (2) | 31/12/2024 | 24/12/2022 - 24/12/2031 | 309.20 | 2,700 | — | 2,700 | — | — | — | — | — | |||||||||||||||
23/12/2022 - 23/12/2025 | 23/12/2022 | (2) | 31/12/2025 | 23/12/2023 - 23/12/2032 | 359.60 | 2,700 | — | — | 2,700 | — | — | 2,700 | — | |||||||||||||||
03/07/2023 - 03/07/2026 | 03/07/2023 | (2) | 31/12/2026 | 03/07/2024 - 03/07/2033 | 355.40 | 1,600 | — | — | 1,600 | — | — | 1,600 | 1,600 | |||||||||||||||
Total | 47,000 | — | 2,700 | 4,300 | — | — | 44,300 | 1,600 | ||||||||||||||||||||
111 | ||
Information regarding the reported financial year | ||||||||||||||||||||||||||||
Opening balance | During the Year | Closing balance | ||||||||||||||||||||||||||
Name of Directors | Performance period | Award date | Vesting date | End of retention period | Exercise period | Exercise price of stock option (€) | Stock options held at the beginning of the year | Stock options awarded | Stock options exercised | Stock options vested | Stock options subject to a service condition | Stock options awarded and unvested | Stock options held at the end of the year | |||||||||||||||